Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Morgan Stanley have increased their stake to 6.5% from 5.5% in Indv. This is a good boost for investors confidence and hopefully should be reflected in the sp going forward. This is definitely a long term hold back to 2000p. A possible 33% uplift from here.
https://www.proactiveinvestors.co.uk/companies/news/1006700/indivior-sell-off-ignores-its-solid-long-term-potential-says-leading-broker-1006700.html
Current SP is a "steal".
I will wait for 1340 if it happen then will load there
Nothing like a share price drop to bring all the bears out of hibernation. The $290 million settlement offer was in the regulatory filings back in November. Where were you posting this before the stock price dropped?
Got in today with 2000 shares. Fantastic opportunity to really make some money here. Don't mind holding for the long term. Litigation is par for the course, every pharma faces the risk at some point. Nearly $850m in the bank set aside a worse case scenario $290 m, and cleverly the tax man got nothing, so great stuff. Should see a steady rise back to 2000 in terms of sp. US markets closed so today most UK stocks were down. Back to normal business tomorrow, expecting 1650 by close tomorrow min.
Good luck with that strategy…
Don’t see it going as low as 14…
It been battered on 2 fronts, the litigation
and a broker downgrade.
Things can and will only get better from
hereonin…
i would be buying back at £14
Jeff now at buy 2115 from 2660.
Falling on a downgrade today by Jefferies.
Looks more like a guillotine ...
This is falling knife at present till clear picture is known from litigations and competition
For another 500 shares at 1605p. Prepared to keep holding and holding so all good.
DYOR,
The operational positives remain in place and good overall execution from management. The provision made is from the DoJ’s anti-competitive practices, with now the civil cases by individual States, the direct purchasers, and indirect payors. This should draw a line on current ligation. These plaintiffs have submitted their claims and as I understand it, Indivior is in mediation to attempt to settle before the 18th Sept 2023 court case. The potential provision, $290M, will hopefully be less and bring closure to these outstanding litigations.
Indivior delivered the anticipated financial performance in 2022. Sales for the year rose ~14% to $901m. A 67% increase in sales of Sublocade to $408m with the moderation in the US sales of Suboxone film at ~$322m, -10%.
Adj. operating profits for 2022 rose ~ 13% to $212m and adj. EPS rose 26% to $1.16. The hoard of net cash and investments on 31 December 2022 was at $751m. In 4Q 2022, Sublocade sales ~$117M vs 4Q2021 @$ ~$75M up +56%. Perseris sale $8M vs 4Q2021 @ 45M +60%. For 4Q 2022 total sales are $241 vs. $221 ~9% up y.o.y, driven by Sublocade sales.
Guidance from the B.o.D for 2023 has revenues expectation in the range of $950M-1,020M ~+9%, with Sublocade sales of $550-600m ~+41% should help drive margins. Perseris sales range of $45-55m ~82%+ With the operating margin expected to increase. On-going sales and margin growth remain in situ for the next 3-5 years as a unique healthcare provider.
Hopefully things will settle and good execution will have the financials support
already recovered 10% ,nice
The upbeat elements of the Results have been almost totally drowned out by the litigation news. Ideal for traders as creates uncertainty. For LTH's its a case of currently sitting this one out as the narrative changes to closure of the Opiant deal and upcoming US listing. Its also not helped that the Dow is nearly 400 points down today.
I couldn't help myself. I got another 500 at 1570p. I'm in for the long haul and hoping they've kitchen sinked these results - worst case - in preparation for Nasdaq float. No more nasty surprises and indeed an improvement on the provision for litigation would then create another spike.
Did you snap up shares in the 1500’s? Looks like a sudden spike past that point.
F**k it, I’m topping up!
Well, not the best of days but in the grand scheme of things still ok. those of us who got in here some time ago are still sat on a massive profit and there isn’t any pharma company out their selling product who isn’t at the risk of litigation. It’s the nature of the business. Suspect this may keep falling today though.
Can anyone who listens to the earnings call please post notes? I’m about to be on a flight for the next few hours.
you are right mate, INDV is down 20% now
Well, that seems to have gone down like a lead balloon!
Strong trading but the quantum of litigation is incredible.. This is a constant risk to the company and I can't see this going away so investors should be mindful of that.
Crossley - "Looking ahead, we expect 2023 to be another year of progress for Indivior, marked by continued strong NR growth of SUBLOCADE and PERSERIS, the planned integration of Opiant and the listing of our shares on NASDAQ. As a proven leader in addiction treatment and science, Indivior is well-positioned to deliver for patients and drive long term value creation for all our stakeholders. I believe our prospects have never been brighter."
Obviously the litigation news was very disappointing and totally over-shadowed the positives on trading . However, I believe that the "litigation effect" on SP will not last that long & many of those who have sold today will buy-back in. INDV (as earlier poster commented) are "clearing the decks" ahead of the US listing. Once the dust has settled the SP will claw back much of today's SP reduction as INDV will be much "cleaner" going forward after making this provision.
I have given this a Strong Buy opinion as anyone (private or II) looking to invest in this market leader, this pull-back (current SP £17.25) represents a great opportunity to buy-in on the cheap.
IMHO, DYOR
Initial mediation sessions in late January 2023 regarding legacy civil multidistrict antitrust litigation provided the Group with new information on
I'm thinking that they're trying to clear the decks prior to the Nasdaq listing - all of the bad news/ provisions in the public realm now - no more nasty surprises. They've tried to re-assure with the 2023 forecasts and on track for further (double digit) growth - sales and profit. Also, at the reduced SP, more of the existing shares being sucked up in the current buyback.